Get started
Author

Helen B Higgins

Observed names: H Higgins, Helen B. Higgins, Helen Higgins, Higgins, Helen
ORCID: 0000-0002-7095-4542
Observed ORCID: 0000-0002-7095-4542
OpenAlex ID: A5042425900
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
2019 · Helena M Earl, Louise Hiller, et al. · The Lancet · 297
PDF
Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial
2019 · Mark T Drayson, Stella Bowcock, et al. · The Lancet Oncology · 172
PDF
The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation
2018 · Leila Rooshenas, Lauren J. Scott, et al. · Journal of Clinical Epidemiology · 97
PDF
PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results.
2018 · Helena Margaret Earl, Louise Hiller, et al. · Journal of Clinical Oncology · 71
An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment
2018 · Marcus Jepson, Daisy Elliott, et al. · Journal of Clinical Epidemiology · 56
PDF
Supportive Self-Management Program for People With Chronic Headaches and Migraine
2022 · Martin Underwood, Felix Achana, et al. · Neurology · 32
PDF
Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT
2020 · Helena Earl, Louise Hiller, et al. · Health Technology Assessment · 21
PDF
Tackling Early Morbidity and Mortality in Myeloma (TEAMM): Assessing the Benefit of Antibiotic Prophylaxis and Its Effect on Healthcare Associated Infections in 977 Patients
2017 · Mark T Drayson, Stella Bowcock, et al. · Blood · 19
ATNEC: A multicenter, randomized trial investigating whether axillary treatment can be avoided in patients with T1-3N1M0 breast cancer with no residual cancer in the lymph glands after neoadjuvant chemotherapy.
2022 · Amit Goyal, Sophie Cramp, et al. · Journal of Clinical Oncology · 15
Non-pharmacological educational and self-management interventions for people with chronic headache: the CHESS research programme including a RCT
2023 · Martin Underwood, Felix Achana, et al. · Programme Grants for Applied Research · 10
PDF
Diagnostic pathways in multiple myeloma and their relationship to end organ damage: an analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) trial
2020 · Catherine Atkin, Gulnaz Iqbal, et al. · British Journal of Haematology · 10
PDF
Chronic Headache Education and Self-Management Study (CHESS): a process evaluation
2023 · David R. Ellard, Vivien P. Nichols, et al. · BMC Neurology · 9
PDF
Does pain self-efficacy predict, moderate or mediate outcomes in people with chronic headache; an exploratory analysis of the CHESS trial
2024 · Siew Wan Hee, Shilpa Patel, et al. · The Journal of Headache and Pain · 8
Variation within and between digital pathology and light microscopy for the diagnosis of histopathology slides: blinded crossover comparison study
2024 · David RJ Snead, Ayesha S Azam, et al. · Health Technology Assessment · 7
“It’s just part of who I am…” Living with chronic headache: voices from the CHESS trial, a qualitative study
2024 · Vivien P. Nichols, David R. Ellard, et al. · BMC Neurology · 5
PDF
Axillary management in T1-3N1M0 breast cancer patients with needle biopsy proven nodal metastases at presentation after neoadjuvant chemotherapy (ATNEC).
2021 · Amit Goyal, Sophie Cramp, et al. · Journal of Clinical Oncology · 5
Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT
2019 · Mark T Drayson, Stella Bowcock, et al. · Health Technology Assessment · 5
PDF
The PERSEPHONE trial: Duration of trastuzumab with chemotherapy in women with HER2-positive early breast cancer.
2012 · Helena Margaret Earl, David A. Cameron, et al. · Journal of Clinical Oncology · 5
Disparity between Ki67 measurements and tumor gene expression tests in patients with hormone-sensitive early breast cancer from the OPTIMA preliminary trial.
2022 · Robert C. Stein, Andrea Marshall, et al. · Journal of Clinical Oncology · 4
Abstract OT1-04-01: ATNEC: A multi-centre, randomised trial investigating whether axillary treatment can be avoided in T1-3N1M0 breast cancer patients with no residual cancer in the lymph glands after neoadjuvant chemotherapy (clinicaltrials.gov: nct04109079)
2022 · Amit Goyal, Sophie Cramp, et al. · Cancer Research · 4
ARTemis: Randomized trial with neoadjuvant chemotherapy for patients with early breast cancer.
2012 · Helena Margaret Earl, C Blenkinsop, et al. · Journal of Clinical Oncology · 4
Abstract GS03-02: Mammographic surveillance in early breast cancer patients aged 50 years or over: results of the Mammo-50 non-inferiority trial of annual versus less frequent mammography
2024 · Janet Dunn, Peter Donnelly, et al. · Cancer Research · 3
Abstract OT1-09-02: ATNEC: A multicentre, randomized trial investigating whether axillary treatment can be avoided in T1-3N1M0 breast cancer patients with no residual cancer in the axillary lymph nodes after neoadjuvant chemotherapy
2023 · Amit Goyal, Sophie Nicholls, et al. · Cancer Research · 2
Stratifying risk of infection and response to therapy in patients with myeloma: a prognostic study
2020 · Ilaria J Chicca, Jennifer LJ Heaney, et al. · Efficacy and Mechanism Evaluation · 2
PDF
OPTIMA: a prospective randomised trial to validate the predictive utility and cost-effectiveness of gene expression test-directed chemotherapy decisions
2016 · Robert Stein, Andreas Makris, et al. · European Journal of Surgical Oncology · 2
Works count: 43
Citation count: 874
H-index: 10
I10-index: 11
Year
Topic
Type